These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38745496)

  • 1. Striking the Balance with a PD-L1×4-1BB Bispecific Antibody.
    Ha J; Grippin AJ; Kim BYS; Jiang W
    Cancer Res; 2024 May; 84(10):1546-1547. PubMed ID: 38745496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
    Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
    Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
    Muik A; Garralda E; Altintas I; Gieseke F; Geva R; Ben-Ami E; Maurice-Dror C; Calvo E; LoRusso PM; Alonso G; Rodriguez-Ruiz ME; Schoedel KB; Blum JM; Sänger B; Salcedo TW; Burm SM; Stanganello E; Verzijl D; Vascotto F; Sette A; Quinkhardt J; Plantinga TS; Toker A; van den Brink EN; Fereshteh M; Diken M; Satijn D; Kreiter S; Breij ECW; Bajaj G; Lagkadinou E; Sasser K; Türeci Ö; Forssmann U; Ahmadi T; Şahin U; Jure-Kunkel M; Melero I
    Cancer Discov; 2022 May; 12(5):1248-1265. PubMed ID: 35176764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
    Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
    Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
    Geuijen C; Tacken P; Wang LC; Klooster R; van Loo PF; Zhou J; Mondal A; Liu YB; Kramer A; Condamine T; Volgina A; Hendriks LJA; van der Maaden H; Rovers E; Engels S; Fransen F; den Blanken-Smit R; Zondag-van der Zande V; Basmeleh A; Bartelink W; Kulkarni A; Marissen W; Huang CY; Hall L; Harvey S; Kim S; Martinez M; O'Brien S; Moon E; Albelda S; Kanellopoulou C; Stewart S; Nastri H; Bakker ABH; Scherle P; Logtenberg T; Hollis G; de Kruif J; Huber R; Mayes PA; Throsby M
    Nat Commun; 2021 Jul; 12(1):4445. PubMed ID: 34290245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.
    Shu F; Punekar SR; Velcheti V; Sanmamed MF; Wang J
    Clin Cancer Res; 2022 Aug; 28(15):3182-3184. PubMed ID: 35648093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.
    Su X; Li J; Xu X; Ye Y; Wang C; Pang G; Liu W; Liu A; Zhao C; Hao X
    J Transl Med; 2024 Aug; 22(1):751. PubMed ID: 39123227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 16. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
    Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
    Xiao Y; Chen P; Luo C; Xu Z; Li X; Liu L; Zhao L
    Cancer Treat Res Commun; 2021; 29():100467. PubMed ID: 34598062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.